Entered into a worldwide agreement to develop and commercialize tivozanib beyond Asia. Under the terms of the agreement, AVEO received $125 million in up-front obligations from Astellas. AVEO is also eligible to receive around $1.3 billion in potential milestones comprised of $575 million in clinical and regulatory milestones, including $90 million regarding the regulatory filings and advertising approval in THE UNITED STATES and European countries for tivozanib as a monotherapy in first-line renal cell carcinoma , along with a lot more than $780 million in commercial milestones.‘The study group that he founded at the Medical University of SC is now among the best-funded lipid research organizations in the U.S. Indeed, the cadre of young scientists he recruited can be developing into one of the leading lipid analysis groups in the world,’ stated Christopher R. McMaster of Dalhousie University in Nova Scotia, Canada. Hannun earned his bachelor’s and medical degrees from American University of Beirut, Lebanon, in 1977 and 1981, respectively.